All In Biotech

Drug Trial Radar · NCT05940428

A Study of ASKG712 in Patients With Diabetic Macular Edema

A Multicenter, Non-Randomized, Open-Label, Multiple-Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASKG712 Following Intravitreal Administration in Patients With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Oct 23, 2023

Primary completion

Oct 21, 2024

Study completion Oct 21, 2024

Sponsor

Lead sponsor
Visara, Inc.Industry
Sponsor type
Industry
Collaborators
Suzhou Aosaikang Biopharmaceutical Co., Ltd.; AskGene Pharma, Inc.
First posted
Jul 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, non-randomized, open-label, multiple-dose-escalation and dose-expansion study will investigate the safety, tolerability, pharmacokinetics and efficacy of ASKG712 following intravitreal administration in patients with diabetic macular edema (DME).

Conditions

  • Diabetic Macular Edema

Interventions

  • ASKG712Biological

    ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ocular adverse events (AEs) of the study eyesTime frame: 24 weeks
  2. Incidence of non-ocular AEsTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.